Purpose of the study Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant condition that leads to significant disability and morbidity, characterised by the formation of heterotopic hard tissues within connective tissues. The condition has an incidence of approximately one per two million people worldwide. There is no known single effective treatment available for FOP. […]
From a readership of 11 in 1988 to more than 2,000 in 2023, the IFOPA newsletter has evolved to inform and connect friends across the world Together with her sister-in-law, Anne, and fellow IFOPA founding member, Nancy Sando, Jeannie Peeper published the first edition of the FOP Connection in 1988. Back then, it looked quite a bit […]
![]Life-Changing](https://foptrust.org/wp-content/uploads/2023/11/Untitled-design.png)
L.I.F.E. Award Grant makes it easier for professional with FOP to work from home Kathleen Degenhardt works from home. She also has FOP, which makes it difficult for her to perform some tasks. She learned about the Harold & Elaine Kaplan Quality of L.I.F.E. Award program while reading the IFOPA monthly newsletter and applied. The program provides […]
Connect with FOP researchers, meet new families and more! You’ll notice a few things are brand new for this year’s In Pursuit of a Cure campaign. But the most important part of the campaign is the same — you! Read on for a quick update on some exciting changes and what they mean to you in the weeks ahead… We’ve supercharged In […]
MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). Palovarotene, an […]
NDA Submission Planned for the Second Half of 2019 MONTREAL, Oct. 23, 2018 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it plans to submit a New Drug Application (NDA) for palovarotene to the U.S. Food and […]
Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced preclinical proof-of-concept data for BLU-782, an investigational oral precision therapy specifically designed to target mutant activin-like kinase 2, the underlying cause of fibrodysplasia ossificans progressiva. Preclinical studies in a well-characterized, genetically accurate FOP model showed […]
Clementia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced updated data from the open label extension (“Part B”) of its ongoing Phase 2 clinical trial of palovarotene in fibrodysplasia ossificans progressiva (FOP). “These updated data continue to support the potential for palovarotene in FOP, […]
Human skeletal stem cells that become bone, cartilage, or stroma cells have been isolated from fetal and adult bones. This is the first time that skeletal stem cells, which had been observed in rodent models, have been identified in humans. The researchers were also able to derive the skeletal stem cells from human induced pluripotent […]
Learn more about Regeneron’s LUMINA-1 clinical trial presented by Dr. Richard Keen from the Royal National Orthopaedic Hospital in England. This webinar is hosted by FOP Friends in the United Kingdom http://fopfriends.com/. Source: FOPnews
